BridGene Biosciences is a biotechnology company developing a chemoproteomic platform. It combines covalent chemistry, chemical proteomics, and quantitative mass spectrometry technologies and focuses on discovering and creating small molecule therapeutics for oncology drug development. The company offers quantitative mass spec analysis, live-cell proteome-wide screening, and a covalent library targeting different amino acids, among other solutions.